Net Cash Provided by (Used in) Financing Activities in USD of RELMADA THERAPEUTICS, INC. from 2012 to 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Summary
RELMADA THERAPEUTICS, INC. quarterly/annual Net Cash Provided by (Used in) Financing Activities history and change rate from 2012 to 2024.
  • RELMADA THERAPEUTICS, INC. Net Cash Provided by (Used in) Financing Activities for the quarter ending 31 Mar 2024 was $222K.
  • RELMADA THERAPEUTICS, INC. annual Net Cash Provided by (Used in) Financing Activities for 2024 was -$40.3K, a 59% increase from 2023.
  • RELMADA THERAPEUTICS, INC. annual Net Cash Provided by (Used in) Financing Activities for 2023 was -$98.5K, a 100% decline from 2022.
  • RELMADA THERAPEUTICS, INC. annual Net Cash Provided by (Used in) Financing Activities for 2022 was $45M, a 76% decline from 2021.
Net Cash Provided by (Used in) Financing Activities, Quarterly (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Quarterly Change (%)
Net Cash Provided by (Used in) Financing Activities, Annual (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Annual Change (%)

RELMADA THERAPEUTICS, INC. Quarterly Net Cash Provided by (Used in) Financing Activities (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 $222K 01 Jan 2024 31 Mar 2024 10-Q 12 May 2025
Q1 2022 $29.9M +$28M +1453% 01 Jan 2022 31 Mar 2022 10-Q 11 May 2023
Q1 2021 $1.93M -$1.08M -35.8% 01 Jan 2021 31 Mar 2021 10-Q 05 May 2022
Q1 2020 $3M +$1.37M +83.3% 01 Jan 2020 31 Mar 2020 10-Q 12 May 2021
Q3 2019 $1.17M +$848K +265% 01 Jul 2019 30 Sep 2019 10-Q 13 Nov 2019
Q1 2019 $1.64M 01 Jan 2019 31 Mar 2019 10-Q 15 May 2020
Q3 2018 $320K -$3.64M -91.9% 01 Jul 2018 30 Sep 2018 10-Q 13 Nov 2019
Q3 2017 $3.96M +$4.06M 01 Jul 2017 30 Sep 2017 10-Q 13 Nov 2018
Q3 2016 -$109K -$21.9K -25.1% 01 Jul 2016 30 Sep 2016 10-Q 10 Nov 2016
Q3 2015 -$87.3K -$4.25M -102% 01 Jul 2015 30 Sep 2015 10-Q 10 Nov 2016
Q3 2014 $4.16M +$1.36M +48.5% 01 Jul 2014 30 Sep 2014 10-Q 06 Nov 2015
Q1 2014 -$45.5K 01 Jan 2014 31 Mar 2014 8-K 27 May 2014
Q3 2013 $2.8M 01 Jul 2013 30 Sep 2013 10-Q 07 Nov 2014

RELMADA THERAPEUTICS, INC. Annual Net Cash Provided by (Used in) Financing Activities (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$40.3K +$58.1K +59% 01 Jan 2024 31 Dec 2024 10-K 27 Mar 2025
2023 -$98.5K -$45.1M -100% 01 Jan 2023 31 Dec 2023 10-K 27 Mar 2025
2022 $45M -$143M -76% 01 Jan 2022 31 Dec 2022 10-K 19 Mar 2024
2021 $188M +$159M +560% 01 Jan 2021 31 Dec 2021 10-K 23 Mar 2023
2020 $28.5M -$97.6M -77.4% 01 Jan 2020 31 Dec 2020 10-K 25 Mar 2022
2019 $126M +$120M +1827% 01 Jan 2019 31 Dec 2019 10-K 24 Mar 2021
2018 $6.54M +$6.82M 01 Jul 2017 30 Jun 2018 10-KT 26 Mar 2020
2017 -$274K -$9.92K -3.76% 01 Jul 2016 30 Jun 2017 10-K 28 Sep 2018
2016 -$264K -$13.4M -102% 01 Jul 2015 30 Jun 2016 10-K 09 Sep 2016
2015 $13.2M 01 Jul 2014 30 Jun 2015 10-K 09 Sep 2016
2013 $4M +$661K +19.8% 01 Jan 2013 31 Dec 2013 10-K 11 Sep 2015
2012 $3.33M 01 Jan 2012 31 Dec 2012 10-KT 09 Sep 2014
* An asterisk sign (*) next to the value indicates that the value is likely invalid.